Drug intelligence / Profile preview

GFT14

Development stage: Discontinued
Lead developer: Genfit
Modality: Small Molecules
Administration: Oral

Overview

GFT14 is a small molecule drug developed as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It was designed for the treatment of cardiometabolic diseases, specifically targeting mixed dyslipidemia of type IIb, which is characterized by high levels of cholesterol and triglycerides. The drug aimed to improve lipid profiles in patients with these metabolic disorders. Development was initially led by Genfit SA but has since been discontinued[1][2][3].

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARD (Peroxisome proliferator–activated receptor delta)

Beyond the preview

Go deeper on GFT14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GFT14.

Explore the full profile